Status:
COMPLETED
Simvastatin Therapy in Patients With Dilated Cardiomyopathy.
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Dilated Cardiomyopathy
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
Dilated cardiomyopathy (DCM) is the most common childhood cardiomyopathy and is associated with significant early morbidity and mortality. About half of patients die or require heart transplantation w...
Detailed Description
Dilated cardiomyopathy (DCM) is the most common childhood cardiomyopathy and is associated with significant early morbidity and mortality. About half of patients die or require heart transplantation w...
Eligibility Criteria
Inclusion
- Patients who have already received anti-congestive medications for at least three months and still have compromised LV function (LVEF \< 45% and the Z score of the LV end-diastolic diameter \> 2.0).
- Patients who have persistent or even worsening heart failure after one month of anti-congestive medications.
- Patients who have positive family history of dilated cardiomyopathy and have received anti-congestive medications for one week.
Exclusion
- Patients who underwent prior cardiac surgery. Those who received DCM related cardiac surgery, such as mitral valve plasty, for longer than a year are not subject to this restriction.
- Patients who had liver / renal dysfunction.
- Patients who are pregnant or plan to pregnancy in the period of study.
- Patients who are intolerance to simvastatin therapy.
Key Trial Info
Start Date :
January 17 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2022
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT03775070
Start Date
January 17 2019
End Date
July 31 2022
Last Update
August 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100